Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.60 |
| ▸ | XIAP | P98170 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | RGS12 | O14924 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499536 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL13537519 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL1249620 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL31453811 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL13537520 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMPTGS1ALPIXIAP | |
| Hydrochloric Acid SCHEMBL20492680 | 0.98 | SLC7A5 (0.58) | SLC7A5PKMPTGS1ALPIXIAP | |
| Hydrochloric Acid SCHEMBL18341961 | 0.98 | SLC7A5 (0.58) | SLC7A5PKMPTGS1ALPIXIAP | |
| Phosphoric Acid SCHEMBL28386744 | 0.89 | SLC7A5 (0.49) | SLC7A5PKMPTGS1ALPIXIAP | |
| Phosphoric Acid SCHEMBL28264743 | 0.89 | SLC7A5 (0.49) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL13971424 | 0.88 | SLC7A5 (0.69) | SLC7A5PKMPTGS1ALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025032025-A1 | STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS | VITROPEP (FR) | 2025-02-13 | — | — | WO | claimed |
| CN-116693771-A | Mud-resistant water reducer and preparation method thereof | 湖南科之杰新材料有限公司 | 2023-09-05 | — | — | CN | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20200146989-A1 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE | UNIVERSITY OF COPENHAGEN (DK) | 2020-05-14 | — | — | US | claimed |
| CN-109011701-B | Oil-water separation material with pH responsiveness and preparation method and application thereof | 华南理工大学 | 2020-04-28 | — | — | CN | claimed |
| EP-3559016-A1 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE | University of Copenhagen (DK) | 2019-10-30 | — | — | EP | claimed |
| CN-106568870-B | A kind of detection method irradiating aquatic products dried product | 舟山出入境检验检疫局综合技术服务中心 | 2019-04-02 | — | — | CN | claimed |
| CN-109011701-A | One kind having pH responsiveness water-oil separating material and the preparation method and application thereof | 华南理工大学 | 2018-12-18 | — | — | CN | claimed |
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | claimed |
| EP-1753719-B1 | SUBSTITUTED PYRROLIDINE-2-ONES | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | claimed |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-06-12 | — | — | US | claimed |
| WO-2008067270-A1 | MACROCYCLIC GRB2 SH2 DOMAIN-BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-06-05 | — | — | WO | claimed |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-07-26 | — | — | US | claimed |
| EP-1793843-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006039527-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-13 | — | — | WO | claimed |
| US-6977241-B2 | SH2 domain binding inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2005-12-20 | — | — | US | claimed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| US-3930948-A | ENZYMATIC METHOD FOR PRODUCING AROMATIC ETHYLAMINES | AJINOMOTO CO., INC. (JA) | 1976-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | ACP1, PPM1D, LASP1 | SLC7A5 1044/4885PKM 3815/4885PTGS1 4075/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | SLC7A5 843/4885PKM 4113/4885PTGS1 4251/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | SLC7A5 378/4885PKM 3229/4885PTGS1 4428/4885 |
| US-20200146989-A1 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE | DNPEP, PEPD, IDUA | SLC7A5 436/4885PKM 3274/4885PTGS1 4309/4885 |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | PRLHR, EPOR, FLT1 | SLC7A5 596/4885PKM 434/4885PTGS1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.